data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

HUTCHMED (China) Ltd

(NASDAQ:HCM)

Perks Buy Compare Brokers

$18.80

0[0.00%]

Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here

$18.80

0[0.00%]

After-Hours

Perks Buy Compare Brokers

Open-	Close-
Vol / Avg.0 / 150.827K	Mkt Cap3.276B
Day Range- - -	52 Wk Range10.680 - 21.280

0

Latest News for HUTCHMED (China) Stock (NASDAQ:HCM)

HUTCHMED (China) Stock (NASDAQ: HCM)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, December 01, 2023

HUTCHMED To Presents New Clinical Data From Several Ongoing Studies With Investigational Drug Candidates Fruquintinib, Surufatinib And HMPL-295 At The Upcoming European Society For Medical Oncology Asia Congress
Benzinga Newsdesk - Dec 1, 2023, 2:25AM

Friday, November 24, 2023

Hutchmed shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $20 to $22.1.
Benzinga Newsdesk - Nov 24, 2023, 10:31AM
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Lisa Levin - Nov 24, 2023, 9:15AM
Deutsche Bank Upgrades HUTCHMED (China) to Buy, Raises Price Target to $22.1
Benzinga Newsdesk - Nov 24, 2023, 5:08AM

Friday, November 10, 2023

Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
Benzinga Insights - Nov 10, 2023, 12:00PM
Goldman Sachs Maintains Neutral on HUTCHMED (China), Raises Price Target to $17
Benzinga Newsdesk - Nov 10, 2023, 11:04AM

Thursday, November 09, 2023

Hutchmed's Partner Takeda Received FDA Approval For Fruzaqla (Fruquintinib) For Previously Treated Metastatic Colorectal Cancer Patients; The Approval Was Received Under Priority Review Over 20 Days Ahead Of The Scheduled Prescription Drug Users Fee
Benzinga Newsdesk - Nov 9, 2023, 6:26AM

Monday, October 30, 2023

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Oct 30, 2023, 1:55PM
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Lisa Levin - Oct 30, 2023, 10:19AM

Friday, October 27, 2023

Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
Lisa Levin - Oct 27, 2023, 11:57AM

Wednesday, October 11, 2023

AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
Lisa Levin - Oct 11, 2023, 11:42AM

Friday, September 29, 2023

HUTCHMED Submits New Drug Application For Fruquintinib For Previously Treated Metastatic Colorectal Cancer In Japan
Benzinga Newsdesk - Sep 29, 2023, 4:59AM

Tuesday, September 12, 2023

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
Benzinga Newsdesk - Sep 12, 2023, 4:41AM
HUTCHMED Concludes Patient Enrollment Of Bridging Study Of Tazemetostat In Patients With Relapsed/Refractory Follicular Lymphoma In China
Benzinga Newsdesk - Sep 12, 2023, 1:56AM

Monday, September 11, 2023

Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Lisa Levin - Sep 11, 2023, 5:35AM

Tuesday, September 05, 2023

Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
Benzinga Newsdesk - Sep 5, 2023, 9:58AM

Tuesday, August 29, 2023

HUTCHMED shares are trading higher after the company's 's Savolitinib was granted Breakthrough Therapy Designation in China.
Benzinga Newsdesk - Aug 29, 2023, 11:02AM
HUTCHMED's Savolitinib Granted Breakthrough Therapy Designation In China For Gastric Cancer Treatment
Benzinga Newsdesk - Aug 29, 2023, 2:13AM

Monday, August 21, 2023

Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
Vandana Singh - Aug 21, 2023, 12:28PM
HUTCHMED's Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint In Primary Immune Thrombocytopenia In China
Benzinga Newsdesk - Aug 21, 2023, 1:21AM

Friday, August 18, 2023

Shares of Chinese stocks are trading lower after property developer, China Evergrande Group, filed for Chapter 15 bankruptcy protection in New York.
Benzinga Newsdesk - Aug 18, 2023, 7:25AM

Monday, August 07, 2023

HUTCHMED shares are trading lower as the stock pulls back after gaining last week.
Benzinga Newsdesk - Aug 7, 2023, 3:29PM
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Aug 7, 2023, 1:28PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Aug 7, 2023, 9:05AM
Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Lisa Levin - Aug 7, 2023, 8:07AM
Sohu.com, Cloudflare And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Lisa Levin - Aug 7, 2023, 6:14AM

Thursday, August 03, 2023

HUTCHMED shares are trading higher on continued strength after the company recently reported a year-over-year increase in H1 financial results.
Benzinga Newsdesk - Aug 3, 2023, 2:18PM

Tuesday, August 01, 2023

Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Aug 1, 2023, 3:05PM
Caterpillar, Oshkosh, AudioCodes And Other Big Stocks Moving Higher On Tuesday
Lisa Levin - Aug 1, 2023, 11:33AM
HUTCHMED shares are trading higher after the company reported a year-over-year increase in H1 financial results.
Benzinga Newsdesk - Aug 1, 2023, 11:15AM

Monday, July 31, 2023

HUTCHMED (China) H1 EPADS $0.97 Up From $(0.96) YoY, Sales $532.87M Up From $202.05M YoY
Benzinga Newsdesk - Jul 31, 2023, 7:43AM
Earnings Scheduled For July 31, 2023
Benzinga Insights - Jul 31, 2023, 6:31AM

Monday, July 24, 2023

Shares of several Chinese companies are trading higher after China earlier announced it has pledged to optimize the business environment for private enterprises ahead of the Politburo meeting later this week.
Benzinga Newsdesk - Jul 24, 2023, 11:20AM
Cantor Fitzgerald Reiterates Overweight on HUTCHMED (China), Maintains $50 Price Target
Benzinga Newsdesk - Jul 24, 2023, 9:53AM

Thursday, July 20, 2023

HUTCHMED Receives Breakthrough Therapy Designation In China For Fruquintinib Combination With Sintilimab
Benzinga Newsdesk - Jul 20, 2023, 1:07AM

Monday, July 10, 2023

HUTCHMED Initiates Phase I Study Of Its Novel SHP2 Inhibitor HMPL-415 For Advanced Malignant Solid Tumors In China
Benzinga Newsdesk - Jul 10, 2023, 12:02AM

Tuesday, June 20, 2023

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights - Jun 20, 2023, 1:38PM
HUTCHMED shares are trading lower amid weakness in China stocks.
Benzinga Newsdesk - Jun 20, 2023, 11:10AM

Friday, June 16, 2023

HUTCHMED shares are trading higher after the company and Takeda announced the publication of Phase III FRESCO-2 results in The Lancet, which showed fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer.
Benzinga Newsdesk - Jun 16, 2023, 2:59PM
Hutchmed And Takeda Announced That Results Of Phase 3 FRESCO-2 Study Of Fruquintinib In Patients With Previously Treated Metastatic Colorectal Cancer Were Published In The Lancet, Showing That Fruquintinib Reduced The Risk Of Death By 34%
Benzinga Newsdesk - Jun 16, 2023, 4:37AM

Thursday, June 15, 2023

HUTCHMED shares are trading higher after the company and Takeda announced the EMA validated and accepted for regulatory review the marketing authorization application for fruquintinib.
Benzinga Newsdesk - Jun 15, 2023, 12:04PM
Takeda And HUTCHMED Announce Marketing Authorization Application Of Fruquintinib For Previously Treated Metastatic Colorectal Cancer Validated By The European Medicines Agency
Benzinga Newsdesk - Jun 15, 2023, 10:32AM

Tuesday, May 30, 2023

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - May 30, 2023, 1:27PM
Shares of Chinese companies are trading lower amid concerns of a slow economic recovery.
Benzinga Newsdesk - May 30, 2023, 11:15AM
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
Lisa Levin - May 30, 2023, 10:58AM

Friday, May 26, 2023

10 Stocks Reacting To April PCE: Marvell Technology Leads The Rally
AJ Fabino - May 26, 2023, 10:18AM
HUTCHMED shares are trading higher after the company and Takeda announced the New Drug Application for fruquintinib for the treatment of previously treated metastatic colorectal cancer was granted priority review.
Benzinga Newsdesk - May 26, 2023, 9:46AM

Thursday, May 25, 2023

HUTCHMED Highlights Presentations At The 2023 ASCO Annual Meeting
Benzinga Newsdesk - May 25, 2023, 6:01PM
Takeda And HUTCHMED Announce New Drug Application For Fruquintinib For Treatment Of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Happy Mohamed - May 25, 2023, 4:32PM

Thursday, May 18, 2023

Shares of several Chinese stocks are trading lower amid weakness in Alibaba.
Benzinga Newsdesk - May 18, 2023, 1:58PM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved